Table of Contents Table of Contents
Previous Page  39 / 64 Next Page
Information
Show Menu
Previous Page 39 / 64 Next Page
Page Background

243

57.- Seymour J F, Presneill J J. Pulmonary alveolar

proteinosis: progress in the first 44 years. Am J Respir

Crit Care Med 2002; 166: 215-35.

58.- Huizar I, Kavuru M S. Alveolar proteinosis syn-

drome: pathogenesis, diagnosis, and management. Curr

Opin Pulm Med 2009; 15: 491-8.

59.- Sverzellati N, Guerci L, Giorgia R, Ca-

labrò E, La Vecchia C, Marchianò A, et al.

Interstitial lung diseases in a lung cancer screening trial.

Eur Respir J 2011; 38: 392-400.

Correspondencia a:

Dr. Juan Carlos Rodríguez D.

Instituto Nacional del Tórax

Av. José M. Infante 717. Providencia.

Santiago de Chile.

Email:

jcerodriguez@gmail.com

60.- Washko G R, Hunninghake G M, Fernán-

dez IE, Nishino M, OkajimaY, Yamashiro T,

et al. Lung volumes and emphysema in smokers with

interstitial lung abnormalities. N Engl J Med 2011; 364:

897-906.

61.- Jin G Y, Lynch D, Chawla A, Garg K, Tam-

memagi M C, Sahin H, et al. Interstitial lung ab-

normalities in a CT lung cancer screening population:

prevalence and progression rate. Radiology 2013; 268:

563-71.

Enfermedades pulmonares difusas relacionadas al tabaco

Rev Chil Enferm Respir 2016; 32: 233-243